Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab in limited-stage small cell lung cancer
NCT05353257Phase 3Active, not recruiting
- Sponsor
- Henlius
- Start
- May 2022
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Serplulimab + Chemotherapy + RT with Placebo + Chemotherapy + RT (2 arms). Primary endpoints: Progression-Free Survival at 24 months and Overall Survival at 36 months. Started May 2022; status: active, not recruiting.
02
Drugs
serplulimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05353257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05353257.